Characterization of ixodid tick salivary-gland gene products, using recombinant DNA technology

1989 ◽  
Vol 7 (1) ◽  
pp. 21-32 ◽  
Author(s):  
Glen R. Needham ◽  
Deborah C. Jaworski ◽  
Frank A. Simmen ◽  
Nour Sherif ◽  
Mark T. Muller
Keyword(s):  
Salivary Gland ◽  
Recombinant Dna ◽  
Ixodid Tick ◽  
Gene Products ◽  
Recombinant Dna Technology ◽  
Dna Technology

Anaerobic synthesis of vitamin B12: characterization of the early steps in the pathway

2005 ◽  
Vol 33 (4) ◽  
pp. 811-814 ◽  
Author(s):  
S. Frank ◽  
A.A. Brindley ◽  
E. Deery ◽  
P. Heathcote ◽  
A.D. Lawrence ◽  
...  
Keyword(s):  
Vitamin B12 ◽  
Biosynthetic Pathway ◽  
Recent Progress ◽  
Recombinant Dna ◽  
Structural Studies ◽  
Recombinant Dna Technology ◽  
Factor Ii ◽  
Dna Technology ◽  
Insight Into

The anaerobic biosynthesis of vitamin B12 is slowly being unravelled. Recent work has shown that the first committed step along the anaerobic route involves the sirohydrochlorin (chelation of cobalt into factor II). The following enzyme in the pathway, CbiL, methylates cobalt-factor II to give cobalt-factor III. Recent progress on the molecular characterization of this enzyme has given a greater insight into its mode of action and specificity. Structural studies are being used to provide insights into how aspects of this highly complex biosynthetic pathway may have evolved. Between cobalt-factor III and cobyrinic acid, only one further intermediate has been identified. A combination of molecular genetics, recombinant DNA technology and bioorganic chemistry has led to some recent advances in assigning functions to the enzymes of the anaerobic pathway.

Characterization of Factor VIII B-Cell Inhibitory Epitopes

1999 ◽  
Vol 82 (08) ◽  
pp. 505-508 ◽  
Author(s):  
Pete Lollar
Keyword(s):  
Factor Viii ◽  
B Cell ◽  
Recombinant Dna ◽  
Bleeding Diathesis ◽  
Recombinant Dna Technology ◽  
C2 Domains ◽  
The Third ◽  
Dna Technology ◽  
Clinically Significant

IntroductionFactor VIII contains three epitopes that are the usual targets of clinically significant antibody inhibitors. Two of these epitopes are located in the A2 and C2 domains of factor VIII. The third epitope appears to be in the A3 domain. Ongoing studies continue to provide higher resolution maps of these epitopes and to understand the mechanism by which inhibitors produce a bleeding diathesis. The manipulation of inhibitor epitopes using recombinant DNA technology may lead to improved forms of factor VIII that have lower antigenicity and/or lower immunogenicity.

scholarly journals Biotin Production by Using Recombinant DNA Technology

1992 ◽  
Vol 38 (Special) ◽  
pp. 263-266
Author(s):  
O. IFUKU ◽  
S. HAZE ◽  
J. KISHIMOTO ◽  
M. YANAGI
Keyword(s):  
Recombinant Dna ◽  
Recombinant Dna Technology ◽  
Dna Technology
Sign in / Sign up

Export Citation Format

Share Document